Jazz Pharmaceuticals plc, (NASDAQ: JAZZ), filed a court order with the New Jersey District Court dismissing the final patent claim against Epidiolex. This drug is used to treat epilepsy caused by cannabis. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) acquired GW Pharmaceuticals that developed Epidiolex as a treatment for rare epilepsy in pediatrics called Dravet Syndrome, and Lennox-Gastaut.
Jazz launched its fight against companies in 2023 by accusing them of patent violations. Teva Pharmaceuticals was one of the companies involved. Others included Apotex Inc. Companies began dropping out quickly after reaching settlements with Jazz.
Apotex appears to be the last company to come to an agreement with Jazz, which accused Apotex of violating 20 Jazz patents. Jazz claimed Apotex asked FDA approval to produce a generic Epidiolex.
Apotex, the final company to settle, was the only one that tried despite some resistance from other companies. In the order it was stated that this case had been,
This case is dismissed with prejudice without cost or fees for the parties.
Success with Epidiolex
Epidiolex became a popular target among competitors because of its success. Green Market Report Epidiolex generated $251.5m in revenue during the third quarter for the company. This is up from the $213.7m in the same quarter last year. For the past nine months ending in September, Epidiolex has generated $697 million in sales – an increase of 15% over the previous year. Epidiolex was the second best seller in this quarter, behind only Xywav – Jazz’s sleeping aid.
The company also announced in December that it achieved positive results for its drug when treating tuberous sclerosis complex (TSC) a rare genetic condition. It is caused by benign tumors that grow in many vital body organs including the brain and skin.
2294000-2294695-https-ecf-njd-uscourts-gov-doc1-119122186850